


Research Initiatives



The Milken Institute Center for Health Economics has emerged as a direct result of the growing scrutiny that businesses and governments are paying to the nation's health. Good health is good for business, but how will the scenario unfold for a country whose aging population faces not just health crises, but health-insurance crises? How can we reduce health disparities by focusing on barriers to


good health? What will encourage and reward advances in clinical practice and research that improve quality of care for those with prevalent and costly diseases?

The Center will pursue research initiatives like *An Unhealthy America: The Economic Burden of Chronic Disease — Charting a New Course to Save Lives and Increase Productivity and Economic Growth*. This study, released in 2007, was the first of its kind to quantify current and future treatment costs, as well as the economic losses for business, across all 50 states. Researchers tracked seven chronic diseases and found the impact on the U.S. economy to be \$1.3 trillion annually, including lost productivity totals of \$1.1 trillion and \$277 billion for treatment.

The Center is undertaking an initiative on the epidemiology and outcomes of hormone refractory prostate cancer (HRPC) patients in the United States. This study is primarily aimed at quantifying

the medical burden of patients diagnosed with HRPC. Our goal is to determine the size of the patient population showing advanced prostate cancer; their treatment patterns (inpatient, outpatient and drug treatment); and the medical costs associated with those patterns. We will also address key technical issues, such as defining advanced prostate cancer through multiple criteria and selecting efficient strategies to treat advanced prostate cancer patients, utilizing two very different datasets.

Avoidable Treatment Costs and Output Losses in 2023 by Chronic Disease



Note: Treatment expenditures for individuals in nursing homes, prisons or under other institutional care not included. Treatment expenditures for comorbidities and secondary effects of listed disease are also excluded.
 Sources: MEPS, NHIS, Milken Institute
 From *An Unhealthy America: The Economic Burden of Chronic Disease*

Some of Our Partners

- | | |
|--|---|
| Partnership to Fight Chronic Disease | AstraZeneca |
| Pharmaceutical Research and Manufacturers of America | Prostate Cancer Foundation |
| The New England Healthcare Institute | Bristol-Myers Squibb |
| U.S. Chamber of Commerce | Chicagoland Chamber of Commerce |
| Biotechnology Industry Organization | BioAdvance |
| National Association of Manufacturers | National Association of Chronic Disease Directors |
| | Nemours Foundation |
| | Deloitte |

US\$Billions
 ■ Direct Costs ■ Indirect Costs

“The report (*An Unhealthy America: The Economic Burden of Chronic Disease*) adds to the growing base of information describing the impact of chronic disease on health-care costs and provides detailed analysis about its influence on the labor supply and the economy through decreased worker productivity.”

— **JudyAnn Bigby, M.D., Secretary of Health and Human Services, State of Massachusetts**

